Results 1 to 10 of about 2,201,777 (199)

Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD [PDF]

Discover Oncology
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the most applied targeted therapy for EGFR-mutant lung adenocarcinoma (LUAD).
Mingxin Liu, Bo Tang, Run Xiang, Peihong Hu, Chuan Xu, Lanlin Hu, Qiang Li   +6 more
doaj   +5 more sources

Hypoxia-induced exosomal LUCAT1 promotes osimertinib resistance in lung adenocarcinoma by stabilizing c-MET [PDF]

Cell Death and Disease
Osimertinib resistance poses a major challenge in treating advanced EGFR-mutant lung adenocarcinoma (LUAD). Exosomes, key mediators of intercellular communication, may contribute to drug resistance, but their specific role in osimertinib resistance ...
Jianting Du, Bin Zheng, Jiekun Qian, Guanglei Huang, Wenjie Yuan, Renjie Huang, Xian Gong, Guobing Xu, Bixing Zhao, Xiaolong Liu, Yingchao Wang, Zhang Yang, Chun Chen   +12 more
doaj   +3 more sources

Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover [PDF]

JCI Insight
Non–small cell lung cancer (NSCLC) is a common cause of cancer-related deaths worldwide, and its incidence has been increasing in recent years. While targeted therapies like osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor, have
Ruirui Wang, Qiang Wang, Jinzhuang Liao, Xinfang Yu, Wei Li   +4 more
doaj   +3 more sources

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC

iScience, 2023
Summary: The mechanisms of osimertinib resistance have not been well characterized. We conducted next-generation sequencing to recognize novel resistance mechanism and used cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models to ...
Rui Han, Caiyu Lin, Chong Zhang, Jun Kang, Conghua Lu, Yiming Zhang, Yubo Wang, Chen Hu, Yong He   +8 more
doaj   +2 more sources

Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization

EBioMedicine, 2022
Summary: Background: The mechanism of missense alteration at EGFR L792F in patients with non-small cell lung cancer resistant to osimertinib has not been sufficiently clarified.
Yiting Sun, Yiting Dong, Xijuan Liu, Yundi Zhang, Hua Bai, Jianchun Duan, Zhihua Tian, Xiang Yan, Jie Wang, Zhijie Wang   +9 more
doaj   +3 more sources

Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells

Thoracic Cancer, 2021
Background Osimertinib is a third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved for the treatment of patients with EGFR‐mutant non‐small cell lung cancer (NSCLC).
Kakeru Hisakane, Masahiro Seike, Teppei Sugano, Akiko Yoshikawa, Kuniko Matsuda, Natsuki Takano, Satoshi Takahashi, Rintaro Noro, Akihiko Gemma   +8 more
doaj   +2 more sources

A Multikinase Inhibitor AX-0085 Blocks FGFR1 Activation to Overcomes Osimertinib Resistance in Non-Small Cell Lung Cancer [PDF]

Biomedicines
Background: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with high efficacy in treating patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations.
Byung-Ho Rhie, Janardhan Keshav Karapurkar, Hyun-Yi Kim, Sang Hyeon Woo, D. A. Ayush Gowda, Dong Ha Kim, Myeong Jun Choi, Young Jun Park, Viswanathaiah Matam, Yoonki Hong, Seok-Ho Hong, Suresh Ramakrishna, Kye-Seong Kim   +12 more
doaj   +2 more sources

The N6-methyladenosine-mediated cLMNB1 degrades FGFR4 to overcome osimertinib resistance in non-small cell lung cancer [PDF]

Cell Death and Disease
Osimertinib resistance is the main challenge in treating EGFR-mutant lung adenocarcinoma (LUAD). The role of N6-methyladenosine (m6A) modification of circular RNAs (circRNAs) in osimertinib-resistant LUAD remains largely unknown.
Yuxian Qian, Hui Wang, Yipeng Feng, Yijian Zhang, Qianfan Hu, Zehao Pan, Xiaodong Zhang, Lin Xu, Li Yin, Gaochao Dong, Xing Zhang, Feng Jiang   +11 more
doaj   +2 more sources

Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR [PDF]

Translational Oncology
Background: Overcoming osimertinib resistance in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is challenging due to unclear mechanisms. We previously reported a NSCLC case with EGFR mutations progressed on osimertinib
Hui Li, Huiting Wei, Tiantian Zhen, Huabin Gao, Huicong Liu, Shuai Zheng, Huijuan Shi, Jiangtao Liang, Fenfen Zhang, Jiecheng Ye, Gengpeng Lin, Anjia Han   +11 more
doaj   +2 more sources

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

Frontiers in Oncology, 2021
The acquired EGFR C797X mutation has been identified as the most notable resistance to osimertinib, and novel secondary mutations of EGFR L718 and L792 residues have also been demonstrated to confer osimertinib resistance, making the choice of medication
Hong-Shuai Li, Guang-Jian Yang, Yan Wang
doaj   +1 more source